Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.8K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.8K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

631
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
631
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

624
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
624
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.8K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

REPLY: Is There an Intramyocardial "Purkinje" System in the Heart?

JACC. Clinical electrophysiology·2025
Same author

Healthspan-lifespan gap differs in magnitude and disease contribution across world regions.

Communications medicine·2025
Same author

MYL4 Identifies Intramural Anatomy of Purkinje Fibers in Human Hearts.

JACC. Clinical electrophysiology·2025
Same author

Maturation of human induced pluripotent stem cell-derived cardiomyocytes promoted by Brachyury priming.

Scientific reports·2025
Same author

Therapeutic effects of platelet-derived extracellular vesicles on viral myocarditis correlate with biomolecular content.

Frontiers in immunology·2025
Same author

Artificial intelligence powers regenerative medicine into predictive realm.

Regenerative medicine·2024

Related Experiment Video

Updated: Apr 29, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.2K

Reparative resynchronization in ischemic heart failure: an emerging strategy.

Satsuki Yamada1, Andre Terzic

  • 1Center for Regenerative Medicine and Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic , Stabile 5, 200 First Street SW, Rochester, MN 55905 , USA terzic.andre@mayo.edu.

Expert Opinion on Biological Therapy
|May 21, 2014
PubMed
Summary

Stem cell therapy offers a promising regenerative approach to treat cardiac dyssynchrony after myocardial infarction. This reparative resynchronization strategy repairs heart tissue, improving synchronization and patient outcomes.

Keywords:
biologicscardiac resynchronization therapyclinical trialdyssynchronyheart failuremyocardial infarctionregenerative medicinestem cells

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.4K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.0K

Related Experiment Videos

Last Updated: Apr 29, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.2K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.4K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.0K

Area of Science:

  • Cardiology
  • Regenerative Medicine
  • Biomedical Engineering

Background:

  • Cardiac dyssynchrony, characterized by uneven cardiac wall motion, is a significant complication of myocardial infarction, leading to poor prognosis.
  • Current device-based cardiac resynchronization therapy is often ineffective in infarct scar tissue, necessitating alternative strategies.
  • Regenerative approaches leveraging tissue repair offer a potential solution for restoring cardiac function.

Discussion:

  • Stem cell therapy has demonstrated potential in preclinical models to reverse contractile deficits in infarcted regions.
  • This regenerative approach promotes long-term cardiac synchronization through tissue repair and functional recovery.
  • Early clinical data suggest that cell-based interventions may benefit patients with acute and chronic ischemic heart disease when used alongside standard treatments.

Key Insights:

  • Stem cell therapy can eliminate contractile deficits caused by myocardial infarction.
  • Reparative resynchronization via stem cells achieves long-term cardiac synchronization and tissue repair.
  • Cell interventions show promise as an adjunct therapy for ischemic heart disease.

Outlook:

  • Further clinical validation is required to establish regenerative resynchronization as a viable treatment option for heart failure.
  • Investigating the mechanisms of stem cell-mediated cardiac repair is crucial for optimizing therapeutic efficacy.
  • Expanding the application of cell-based therapies could revolutionize the management of dyssynchronous heart failure.